New cocktail therapy aims to tackle Drug-Resistant lung cancer
NCT ID NCT07416058
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of the experimental drug QL1706, standard chemotherapy, and bevacizumab can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has specific gene changes and has stopped responding to targeted therapy. About 61 participants will receive the treatment in 3-week cycles for up to 2 years. The main goal is to see if the tumor response rate improves compared to historical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a drug that targets PD-1 and CTLA-4), bevacizumab, pemetrexed, and platinum chemotherapy (cisplatin or carboplatin)
- What this could lead to
- If this works, it could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to targeted therapy.
- What could go wrong
- This is a small, early-phase trial with no comparison group, so results may not be definitive. The combination of multiple drugs also increases the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI be a Pathologist's second opinion?
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- Blood tests could unlock early clues for three major lung diseases
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Why some Never-Smokers get lung cancer: a new study investigates